November 18, 2011
ImmunoCellular Therapeutics Ltd. (OTCBB: IMUC), a biopharmaceutical company developing new therapeutics to fight cancer using the immune system, is taking a different approach than companies like ImmunoGen Inc. (NASDAQ: IMGN) and Immunomedics Inc. (NASDAQ: IMMU) by targeting cancer stem cells (CSCs) to prevent instances of recurrence.
Recently, the company announced that it would be presenting at the 16th annual meeting of the Society for Oncology. The company will give a presentation entitled, “A cancer vaccine targeting cancer stem cell antigens (ICT-107) demonstrates correlated tumor antigen expression and progression free survival and may reduce the cancer stem cell population in recurrent tumors.”
Here’s a copy of the complete press release from ImmunoCellular:
ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (OTCBB: IMUC.OB), a biotechnology company focused on the development of novel immune-based therapies, today announced that John Yu, MD, Chairman of ImmunoCellular Therapeutics, will take part in the 16th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) to be held at the Hyatt Regency, Orange County, California from November 17-20, 2011. SNO is the premier professional society comprising neuro-oncologists from across the U.S. and abroad.
The Company’s presentation titled, “A cancer vaccine targeting cancer stem cell antigens (ICT-107) demonstrates correlated tumor antigen expression and progression free survival and may reduce the cancer stem cell population in recurrent tumors,” will be presented at 7:30 p.m. on Friday, November 18, 2011 at the Hyatt Hotel in Orange County, California. It discusses updated data on antigen expression and immune response referencing correlations of increased progression-free survival (PFS) and overall survival (OS) from the Company’s Phase I clinical trial of ICT-107. Of the 16 patients in the study, 6 showed no signs of tumor recurrence, with 3 experiencing no disease progression over 4 years after vaccination, while the other three have been disease free for at least 3 years. The expression of four out of six ICT-107 antigens in the pre-vaccine tumors correlates with prolonged PFS and OS in newly diagnosed GBM patients. The goal of targeting tumor antigens highly expressed on glioblastoma cancer stem cells is supported by the observation of decreased or absent CD133 expression in patients with recurrent tumors. ICT-107 may thus immunologically target the cancer stem cell population of glioblastoma.
In the Company presentation at the symposium, “Current State of the Art: Vaccine Development In The Treatment of GBM,” on Saturday, November 19, 2011, starting at 12:00 p.m., Dr. Yu will discuss the encouraging prior clinical data for ICT-107, and the ongoing Phase-II double-blind, placebo-controlled, 2:1 randomized study designed to evaluate the safety and efficacy of ICT-107 in patients with newly diagnosed GBM. The study will enroll approximately 160 patients at more than 20 clinical trial centers in the U.S. in collaboration with leading experts and opinion leaders in neuro-oncology.
Manish Singh, CEO of ImmunoCellular Therapeutics, said, “We are excited to participate in this premier gathering of medical professionals specializing in neuro-oncology. We believe that it is a great opportunity to update these specialists to the exciting progress being made in our development of ICT-107.”
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. To learn more about the Company, please visit www.imuc.com.
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that the safety and efficacy results obtained in the Phase I trial for ICT-107 will not be confirmed in subsequent trials. Additional risks and uncertainties are described in IMUC’s most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.